NightWare Receives FDA Marketing Permission for First and Only Medical Device to Reduce Sleep Disturbances Related to PTSD-Associated Nightmares in Adults
Summary
MINNEAPOLIS--(BUSINESS WIRE)--NightWare, a medical device company focused on treating people with nightmares related to post-traumatic stress disorder (PTSD) and other traumatic events, has announced it has received U.S. Food and Drug Administration (FDA) marketing permission for the NightWare™ therapeutic platform. Founded in 2017, NightWare is a privately held, commercial-stage medical device company whose mission is to help people with traumatic nightmares get a more restful nights sleep. Prevalence of mental health problems and functional impairment among active component and National Guard soldiers 3 and 12 months following combat in Iraq. Baseline self reported functional health and vulnerability to post-traumatic stress disorder after combat deployment: Prospective US military cohort study. • Smith TC, Ryan MA, Wingard DL, Slymen DJ, Sallis JF, Kritz-Silverstein D. New onset and persistent symptoms of post-traumatic stress disorder self reported after deployment and combat exposures: Prospective population based US military cohort study.